As a first step in identifying and characterizing CTCs in cancer patients we examined blood cells using immunofluorescence with antibodies against EpCAM, a widely used biomarker for cancers of the epithelial lineage [14, 34–37]. This evidence concerns the gene EPCAM and cancer.